ALIVUS.BO Earnings — Alivus Life Sciences Limited

BSE

Updated Oct 30, 2026

Price —

Market Cap $171.6B

P/E 25.7

52W Range — – —

When is ALIVUS.BO's next earnings date?

Alivus Life Sciences Limited (ALIVUS.BO) has not announced its next earnings date yet. Its most recent earnings report was on Friday, October 30, 2026.

How did ALIVUS.BO do in its last earnings report?

In its most recent report on Oct 30, 2026, Alivus Life Sciences Limited posted EPS of $12.50 versus the $12.50 estimate, an in-line result. Revenue was $6.42B against a $6.42B estimate.

How much does ALIVUS.BO stock move after earnings?

ALIVUS.BO beat EPS estimates in 1 of its last 2 reported quarters.

About Alivus Life Sciences Limited

Alivus Life Sciences Limited, established in Mumbai, India, in 2001, is a pharmaceutical company that handles the full spectrum of active pharmaceutical ingredient (API) operations, from initial development and meticulous production to widespread market distribution. Its comprehensive portfolio of APIs includes compounds like olmesartan, telmisartan, sitagliptin, zonisamide, rosuvastatin, and palbociclib, addressing a broad range of medical needs. These encompass treatments for cardiovascular conditions, neurological disorders, diabetes, digestive health issues, cancer, pain management, immunosuppression, respiratory and ophthalmological ailments, urological concerns, and anti-infective applications. The company boasts a significant global presence, exporting its products to diverse markets across India, Japan, Europe, and both North and Latin America. Beyond its own product lines, Alivus also provides specialized contract development and manufacturing (CDMO) solutions to a variety of multinational corporations and niche pharmaceutical firms. Formerly known as Glenmark Life Sciences Limited, the company transitioned to its current name in December 2024 and operates as a subsidiary of Nirma Limited.

🤖 AI Earnings Analysis

ALIVUS.BO trades at 25.7× earnings with a strong 22.1% profit margin; without news or guidance data, valuation and profitability are the clearest signals.

AI-generated summary — powered by BigEarnings.